127 related articles for article (PubMed ID: 36827074)
21. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.
Demirkol Canlı S; Seza EG; Sheraj I; Gömçeli I; Turhan N; Carberry S; Prehn JHM; Güre AO; Banerjee S
Carcinogenesis; 2020 Sep; 41(9):1219-1228. PubMed ID: 32628753
[TBL] [Abstract][Full Text] [Related]
23. Aldo-keto reductases in the eye.
Huang SP; Palla S; Ruzycki P; Varma RA; Harter T; Reddy GB; Petrash JM
J Ophthalmol; 2010; 2010():521204. PubMed ID: 20628518
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Liu R; Zheng S; Yang CY; Yu Y; Peng S; Ge Q; Lin Q; Li Q; Shi W; Shao Y
Medicine (Baltimore); 2021 Apr; 100(14):e25454. PubMed ID: 33832153
[TBL] [Abstract][Full Text] [Related]
25. Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Kikuya M; Furuichi K; Hirao T; Endo S; Toyooka N; Ito K; Aoki S
J Pharmacol Sci; 2021 Sep; 147(1):1-8. PubMed ID: 34294359
[TBL] [Abstract][Full Text] [Related]
26. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
27. Aldo-keto reductases as modulators of stress response.
Chang Q; Harter TM; Rikimaru LT; Petrash JM
Chem Biol Interact; 2003 Feb; 143-144():325-32. PubMed ID: 12604219
[TBL] [Abstract][Full Text] [Related]
28. Characterization of AKR1B16, a novel mouse aldo-keto reductase.
Giménez-Dejoz J; Weber S; Barski OA; Möller G; Adamski J; Parés X; Porté S; Farrés J
Chem Biol Interact; 2017 Oct; 276():182-193. PubMed ID: 28322781
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma.
Hung JJ; Yeh YC; Hsu WH
Thorac Cancer; 2018 Nov; 9(11):1492-1499. PubMed ID: 30253058
[TBL] [Abstract][Full Text] [Related]
30. cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3.
Knight LP; Primiano T; Groopman JD; Kensler TW; Sutter TR
Carcinogenesis; 1999 Jul; 20(7):1215-23. PubMed ID: 10383892
[TBL] [Abstract][Full Text] [Related]
31. [Downregulation of AKR1B10 gene expression in colorectal cancer].
Kropotova ES; Tychko RA; Zinov'eva OL; Zyrianova AF; Khankin SL; Cherkes VL; Aliev VA; Beresten' SF; Oparina NIu; Mashkova TD
Mol Biol (Mosk); 2010; 44(2):243-50. PubMed ID: 20586184
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of Copines-1 is associated with clinicopathological parameters and poor outcome in gastric cancer.
Yang J; Wang Y; Ge R; Jia X; Ge C; Cen Y; Pan D
J Clin Lab Anal; 2022 Nov; 36(11):. PubMed ID: 36310511
[TBL] [Abstract][Full Text] [Related]
33. Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells.
Matsunaga T; Kawabata S; Yanagihara Y; Kezuka C; Kato M; Morikawa Y; Endo S; Chen H; Iguchi K; Ikari A
Chem Biol Interact; 2019 Dec; 314():108839. PubMed ID: 31563593
[TBL] [Abstract][Full Text] [Related]
34. Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates.
Weber S; Salabei JK; Möller G; Kremmer E; Bhatnagar A; Adamski J; Barski OA
J Biol Chem; 2015 Mar; 290(10):6531-45. PubMed ID: 25577493
[TBL] [Abstract][Full Text] [Related]
35. Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Laffin B; Petrash JM
Front Pharmacol; 2012; 3():104. PubMed ID: 22685431
[TBL] [Abstract][Full Text] [Related]
36. Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Hevir N; Sinkovec J; Lanišnik Rižner T
Chem Biol Interact; 2013 Feb; 202(1-3):226-33. PubMed ID: 23146748
[TBL] [Abstract][Full Text] [Related]
37. A new nomenclature for the aldo-keto reductase superfamily.
Jez JM; Flynn TG; Penning TM
Biochem Pharmacol; 1997 Sep; 54(6):639-47. PubMed ID: 9310340
[TBL] [Abstract][Full Text] [Related]
38. The roles of aldo-keto reductases in steroid hormone action.
Bauman DR; Steckelbroeck S; Penning TM
Drug News Perspect; 2004 Nov; 17(9):563-78. PubMed ID: 15645014
[TBL] [Abstract][Full Text] [Related]
39. A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1.
Zhao H; Dong X; Huang T; Li X
Comput Intell Neurosci; 2022; 2022():9979200. PubMed ID: 35341178
[TBL] [Abstract][Full Text] [Related]
40. Aldo-keto reductases in which the conserved catalytic histidine is substituted.
Di Costanzo L; Penning TM; Christianson DW
Chem Biol Interact; 2009 Mar; 178(1-3):127-33. PubMed ID: 19028475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
